Clinical and demographic characteristics of 165 patients with lichen planus

Objective: Lichen planus (LP), is a papulosquamous inflammatory disease, which involves the skin, mucous membranes, nails and scalp. The incidence varies according to geographical regions. In this study, it was aimed to detect the clinical and demographic characteristics of the patients with LP who have been under follow-up at our clinic. Methods: One hundred sixty five patients, who were diagnosed as LP in our clinic between 2010 and 2013, were enrolled to the study. The age, gender, disease duration, time of onset of disease, characteristics of involvement, associated systemic diseases, laboratory findings and treatment were recorded retrospectively. Results: In our study, 0.6% of all patients admitted to our clinic were diagnosed as LP. A total of 165 patients included in the study, 92 women (56%) and 73 men (44%), respectively. Patients’ ages ranged 8-78 (mean 44.7±16.7). Disease duration ranged from 1 month to 20 years (mean 15.6±29.7). One hundred thirty four patients (81.2%) had skin involvement, 51 (31%) had oral mucosal involvement, and 15 (9%) had genital involvement. Five (4.5%) of 111 patients with viral hepatitis tests were positive for hepatitis C virus. Hepatitis B virus positivity was seen in 4 (4%) patients. Conclusion: There is a need for further studies with more patients to better understand the epidemiological, clinical and pathological characteristics of LP. We believe that our study will contribute to the determination of our country’s data

Scleredema diabeticorum partially treated with low-dose methotrexate : A report of five cases

Skleredema nadir görülen skleroderma-benzeri bir grup konnektif doku hastalıklarından biridir. Bilinen küratif bir tedavisi olmamakla birlikte literatürde birçok tedavi şekli bildirilmiştir. Burada düşük-doz metotreksate tedavisine kısmen cevap veren 5 olgu sunulmaktadır. Tüm hastalar aynı zamanda tip II diyabetes mellitus hastası idi. Tüm hastalara 3 ay süre ile subkutan yolla 15mg/hafta metotreksate tedavisi verildi. Tüm hastalaradan tedavi öncesi ve tedavi sonrası biyopsi alınarak karşılaştırıldı. Tüm hastaların bu tedaviye kısmen cevap verdiği histopatolojik olarak gösterildi. Sonuç olarak, düşük doz metotreksate tedavisi skleredema için alternatif bir tedavi metodu olabilir.Scleredema is a rare connective tissue disorder that belongs to a group of scleroderma-like disorders. Although no known curative therapy exists, various specific treatments have been proposed in the literature. In this report, we describe five cases of scleredema partially treated with low-dose methotrexate therapy. All patients have diabetes mellitus type II. All patients were started on methotrexate 15 mg subcutaneously once weekly for 3 months. Biopsy specimens were taken from all patients and were examinated histologically before the treatment and after 3 months of treatment. All cases partially responded to low-dose methotrexate therapy. We believe that methotrexate therapy may be an alternative therapeutic options in scleredema in view of its efficacy

Head and neck space infection presenting with Herpes Simplex virus

Altı yaşında kız çocuğu submandibüler, submental ve mastikatör alanda şişme, trismus, ağrı ve trigeminal sinirin (C5, V3) mandibüler dalı üzerinde veziküler lezyon yakınmasıyla kliniğimize başvurdu. Baş- boyun alan enfeksiyonu ile tipik Herpes Simpleks virüsü veziküler lezyon birlikteliği olan bu olgu, nadir rastlandığı için sunuldu.A six-year-old girl was admitted to our clinic with the complaints of swelling, trismus, pain in the submandibular, submental and masticator area and vesicular lesions on the mandibular branch of trigeminal nerve (C5, V3). We present this case of head and neck space infection presenting with Herpes Simplex virus, as it is rarely seen

Scleredema Diabeticorum Partially Treated with Low-Dose Methotrexate: a Report of Five Cases

Scleredema is a rare connective tissue disorder that belongs to a group of scleroderma-like disorders. Although no known curative therapy exists, various specific treatments have been proposed in the literature. In this report, we describe five cases of scleredema partially treated with low-dose methotrexate therapy. All patients have diabetes mellitus type II. All patients were started on methotrexate 15 mg subcutaneously once weekly for 3 months. Biopsy specimens were taken from all patients and were examinated histologically before the treatment and after 3 months of treatment. All cases partially responded to low-dose methotrexate therapy. We believe that methotrexate therapy may be an alternative therapeutic options in scleredema in view of its efficacy

''Boğazın Boğası'' Sinan Şamil Sam ve döneminde Türkiye'de boks

Ankara : İhsan Doğramacı Bilkent Üniversitesi İktisadi, İdari ve Sosyal Bilimler Fakültesi, Tarih Bölümü, 2018.This work is a student project of the Department of History, Faculty of Economics, Administrative and Social Sciences, İhsan Doğramacı Bilkent University.The History of Turkey course (HIST200) is a requirement for all Bilkent undergraduates. It is designed to encourage students to work in groups on projects concerning any topic of their choice that relates to the history of Turkey. It is designed as an interactive course with an emphasis on research and the objective of investigating events, chronologically short historical periods, as well as historic representations. Students from all departments prepare and present final projects for examination by a committee, with 10 projects chosen to receive awards.Includes bibliographical references (page 16)by Fatma Özden Mercan

Relationship between serum resistin and lipid levels in patients with psoriasis

Amaç: Psöriasis, artmış kardiyovasküler hastalık (KVH) riski bulunan inflamatuar deri hastalığıdır. Henüz etyolojisi tam olarak belirlenememiştir. KVH'da yağ dokusundan salgılanan resistinin serum total kolesterol, LDL, trigliserid seviyeleriyle pozitif korelasyon gösterdiği belirtilmiştir. Bizim çalışmamızda da amacımız serum resistin seviyeleriyle lipid profilinin psoriasis hastalarında ilişkisini ve Psöriazis alan şiddet endeksi (PAŞİ) ile korelasyonunu araştırmaktır. Materyal ve Metod: Mustafa Kemal Üniversitesi Tıp Fakültesi Dermatoloji polikliniğine başvuran sağlıklı kişilerden kontrol grubu; grup I (n=34) ve psoriasis tanısı konulan hastalardan hasta grubu; grup II (n=37) olmak üzere iki grup oluşturuldu. Yaş, cinsiyet, tansiyon, BMI değerleri ve PAŞİ skorlaması tespit edildi. Gruplardan toplanan serum örneklerinde resistin seviyesi, lipid profiline bakıldı. Bulgular: Psoriasis hastalarını kontrol grubuyla kıyaslandığında serum resistin seviyeleri (grup I: 6,4±2,3 ng/ml; grup II: 12,3±3,0 ng/ml), total kolesterol (grup I: 167±31 mg/dl; grup II: 189±43 mg/dl), LDL seviyeleri (grup I: 90±21 mg/dl; grup II: 129±31 mg/dl) anlamlı olarak hastalarda yüksek tespit edildi (sırasıyla p=0.001; p<0,05; p=0,01). Serum resistin seviyesiyle LDL kolesterolün pozitif korelasyon gösterdiği saptandı (r=0,306). PAŞİ skorlamasının serum resistin seviyeleriyle güçlü pozitif korelasyon gösterdiği tespit edildi (r=0,669). Sonuç: Psoriasis hastalığında artan kardiyovasküler hastalık riskin olduğu bilinmektedir. Bizim çalışmamızda da kardiyovasküler hastalıkta arttığı tespit edilmiş resistin ve total kolesterol ve LDL seviyelerinin psoriasis hastalarında arttığı ve hastalığın şiddetini gösteren PAŞİ skorlamasıyla korele olduğu bulunmuştur. Hastalığın şiddetinin artmasıyla yükselmiş olabileceğini tespit ettiğimiz resistin seviyesinin psoriasis hastalarında lipid profili kadar çalışılmasının anlamlı olabileceği düşünülmektedirPurpose: Psoriasis is inflammatory skin disease which has increased risk of cardiovascular disease. The etiology is unknown, yet. In cardiovascular disease, resistin which is secreted from adipose tissue, was found correlated with the levels of total cholesterol and LDL. In our study, we aimed to study the relation of serum resistin and lipid levels in patients with psoriasis and correlation of Psoriasis Area and Severity Index (PASI). Material and Methods: In Mustafa Kemal University, Faculty of Medicine, Department of Dermatology, thirty-seven healthy subjects (group I) and thirty-four patients with psoriasis (group II) were enrolled for two groups. The age, gender, blood pressure, body mass index (BMI) and PASI were determined. The level of resistin and lipid profile were studied in serum. Results: The level of resistin in patients with psoriasis (12,3&plusmn;3,0 ng/ml) was found increased compared with healthy subjects (6,4&plusmn;2,3 ng/ml) (p=0.001). The level of total cholesterol and LDL were increased in patients with psoriasis compared with healthy subjects, respectively (189&plusmn;43 mg/dl;129&plusmn;31 mg/dl) (p&lt;0,05; p=0,01). The level of resistin was determined correlated positively with LDL (r=0,306). The level of resistin was found strong correlated positively with PASI (r=0,669). Conclusion: The high risk of cardiovascular disease in patients with psoriasis is known. In our study, the levels of resistin, total cholesterol, LDL which increase in cardiovascular disease, was found increased in patients with psoriasis and correlated with PASI. The level of resistin may be increased with increasing severity of the disease, so that it is thought to be significant determining like the lipid profile in patients with psoriasi

Gender-related clinical and management differences in patients with chronic heart failure with reduced ejection fraction

WOS: 000588830800001PubMed: 33063424Aim Gender-related differences have been described in the clinical characteristics and management of patients with chronic heart failure with reduced ejection fraction (HFrEF). However, published data are conflictive in this regard. Methods We investigated differences in clinical and management variables between male and female patients from the ATA study, a prospective, multicentre, observational study that included 1462 outpatients with chronic HFrEF between January and June 2019. Results Study population was predominantly male (70.1%). in comparison to men, women with chronic HFrEF were older (66 +/- 11 years vs 69 +/- 12 years, P < .001), suffered more hospitalisations and presented more frequently with NYHA class III or IV symptoms. Ischaemic heart disease was more frequent in men, whereas anaemia, thyroid disease and depression were more frequent in women. No difference was seen between genders in the use rate of renin-angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, or ivabradine, or in the proportion of patients achieving target doses of these drugs. Regarding device therapies, men were more often treated with an implantable cardioverter-defibrillator (ICD) and women received more cardiac resynchronisation therapy. Conclusion in summary, although management seemed to be equivalent between genders, women tended to present with more symptoms, require hospitalisation more frequently and have different comorbidities than men. These results highlight the importance of gender-related differences in HFrEF and call for further research to clarify the causes of these disparities. Gender-specific recommendations should be included in future guidelines in HFrEF

Adherence to guideline-directed medical and device Therapy in outpAtients with heart failure with reduced ejection fraction: The ATA study

Objective: Despite recommendations from heart failure guidelines on the use of pharmacologic and device therapy in patients with heart failure with reduced ejection fraction (HFrEF), important inconsistencies in guideline adherence persist in practice. The aim of this study was to assess adherence to guideline-directed medical and device therapy for the treatment of patients with chronic HFrEF (left ventricular ejection fraction ?40%). Methods: The Adherence to guideline-directed medical and device Therapy in outpAtients with HFrEF (ATA) study is a prospective, multicenter, observational study conducted in 24 centers from January 2019 to June 2019. Results: The study included 1462 outpatients (male: 70.1%, mean age: 67±11 years, mean LVEF: 30%±6%) with chronic HFrEF. Renin–angiotensin system (RAS) inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and ivabradin were used in 78.2%, 90.2%, 55.4%, and 12.1% of patients, respectively. The proportion of patients receiving target doses of medical treatments was 24.6% for RAS inhibitors, 9.9% for beta-blockers, and 10.5% for MRAs. Among patients who met the criteria for implantable cardioverter–defibrillator (ICD) and cardiac resynchronization therapy (CRT), only 16.9% of patients received an ICD (167 of 983) and 34% (95 of 279) of patients underwent CRT (95 of 279). Conclusion: The ATA study shows that most HFrEF outpatients receive RAS inhibitors and beta-blockers but not MRAs or ivabradin when the medical reasons for nonuse, such as drug intolerance or contraindications, are taken into account. In addition, most eligible patients with HFrEF do not receive target doses of pharmacological treatments or guideline-recommended device therapy. (Anatol J Cardiol 2020; 24: 32-40) Keywords: adherence, chronic heart failure, device therapy, guidelines, pharmacological treatment, outpatient